article
Under the microscope with Labcyte
Dr Sheraz Gul, Head of Assay Development and Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology, answers questions on assay procedures...
List view / Grid view
Issue #1 2017
article
Assays In-Depth Focus 2017
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
article
Biomarkers In-Depth Focus 2017
Drug developers sometimes think of imaging as an emerging discipline. But John Waterton, Paul Hockings, Juliana Maynard and Caleb Roberts explain how imaging biomarkers are transforming drug development. Francesco Gatto and Jens Nielsen, from the Chalmers University of Technology in Sweden, discuss moving towards systems biomarkers for cancer diagnosis...
article
Antibodies In-Depth Focus 2017
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
article
Q&A: Lou Matis on bispecific antibodies
Drug Target Review Editor Steve Bremer talks to Pieris’ Chief Development Officer Lou Matis about bispecific antibodies.
article
Targeting GAS6 in cancer, fibrosis and viral infection
The growth-arrest specific 6 (GAS6) protein has emerged in recent years as an attractive target for drug development primarily because it is the sole ligand for the AXL receptor tyrosine kinase, which plays critical roles in cancer, fibrosis, and viral infection.
article
Nanoparticle-mediated enzyme delivery for application in cancer therapy
Enzyme therapy is a promising form of cancer treatment. The specific nature of enzyme and substrate interaction gives enzyme therapy an edge compared to standard non-specific therapies such as radiation and chemotherapy. However, since most of these enzymes are of a foreign nature, the delivery of these immunogenic enzymes has…
article
Drug Target Review – Issue #1 2017
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
article
Developability assessment of therapeutic antibodies
Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…
article
Towards systems biomarkers for cancer diagnosis
Cancer is asymptomatic during most of its pathogenesis. It is very difficult to see that a cancer is growing in a person, except for a few self-evident cases such as skin cancer. Its intangibility and year-, if not decade-long progression make cancer hard to diagnose until some symptoms warrant further…
article
Whole animal screening: back to the future
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
article
How imaging biomarkers are transforming drug development
Drug developers sometimes think of imaging as an emerging discipline, full of esoteric technologies of marginal relevance to real-world clinical drug development. In fact, the opposite is true: imaging measurements (imaging biomarkers) are used daily in drug development and in personalised medicine. They assess target engagement and receptor occupancy in…
article
High-throughput screening platforms incorporating physiologically relevant 3-D models
Two-dimensional monolayer cell proliferation assays for cancer drug discovery have enabled large-scale screens. But they represent a simplified view of oncogenes or tumour suppressor genes as the genetic drivers of cancer cell proliferation.